Signaling of IL-4 and IL-13–two of the key drivers of type 2 inflammation–
plays an important role in PN3,4
Increased IL-4 and IL-13 signaling directly enhances stimulation of sensory neurons and also leads
to dysregulation of the immune system and skin, resulting in the itch-scratch cycle and the
formation of nodules4-11
THE DISTINCT AND
OVERLAPPING ROLES OF
IL‑4
AND IL‑134‑11
The unique role of IL-4 IN TYPE 2 INFLAMMATION
IL-4 is an orchestrator of Th2
response, creating a positive
feedback
loop that leads to dysregulated
secretion of IL-4,
IL-13, and IL-3112,b
bType 2 cytokines (such as IL-4, IL-13, and IL-31)
may also be produced by other immune cells, such
as ILC2.13,14
bType 2 cytokines (eg, IL-4/IL-13/IL-31) may also be
produced by other immune cells, such as
ILC2.13,14
DUPIXENT is the only dual inhibitor of IL-4 and IL-13 signaling1,2
INHIBITION OF IL-4 AND IL-13
SIGNALING HAS A SUBSTANTIAL
IMPACT ON DISEASE
HELPS REDUCE TYPE 2
INFLAMMATION1,3-6,11
HELPS REDUCE
ITCH1,7,15-17
HELPS ACHIEVE
NODULE CLEARANCE1,8-10
- May break itch-scratch cycle
- May reduce nerve sensitization
- Helps reduce skin fibrosis
The mechanism of dupilumab action has not been definitively established.
c Dimerization is when 2 protein subunits combine to form a larger complex. Complex IL-4 signaling through type 1 receptor requires dimerization of
IL-4Rα with the gamma chain. IL-4 or IL-13 signaling through type 2 receptor requires dimerization of IL-4Rα with IL-13Rα1.
Identifying DUPIXENT patients
Consider whether your patient with prurigo nodularis may be a
candidate for DUPIXENT. Take a look at real DUPIXENT stories.